 | Up a level |
Haddad, Robert; Guigay, Joel; Keilholz, Ulrich; Clement, Paul M; Fayette, Jérôme; de Souza Viana, Luciano; Rolland, Frédéric; Cupissol, Didier; Geoffrois, Lionnel; Kornek, Gabriela; Licitra, Lisa; Melichar, Bohuslav; Ribaldo Nicolau, Ulisses; Rauch, Daniel; Zanetta-Devauges, Sylvie; Cohen, Ezra E W; Machiels, Jean-Pascal; Tahara, Makoto; Vermorken, Jan; Geng, Yuan; ... (2019). Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral oncology, 97, pp. 82-91. Elsevier 10.1016/j.oraloncology.2019.08.004
Gao, Shan; Bajrami, Ilirjana; Verrill, Clare; Kigozi, Asha; Ouaret, Djamila; Aleksic, Tamara; Asher, Ruth; Han, Cheng; Allen, Paul; Bailey, Deborah; Feller, Stephan; Kashima, Takeshi; Athanasou, Nicholas; Blay, Jean-Yves; Schmitz, Sandra; Machiels, Jean-Pascal; Upile, Nav; Jones, Terry M; Thalmann, George; Ashraf, Shazad Q; ... (2014). Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. Cancer research, 74(20), pp. 5866-5877. American Association for Cancer Research AACR 10.1158/0008-5472.CAN-14-0806
